Peripheral Arterial Disease and the need for a SIGN Guideline

Scope of the problem: PAD is underdiagnosed and undertreated

Atherosclerotic disease affecting the arteries of the legs represent a large and growing health burden throughout Europe. It is estimated that peripheral arterial disease (PAD) may affect more than 20% of elderly people worldwide\(^1,2\). The burden of aging multimorbid PAD patients with several significant vascular problems is rising\(^2\) and their outcome is very poor.

Secondary care data on PAD patients shows that the prognosis of many PAD patients is as bad as that of patients with Duke’s stage 2b colon cancer\(^3\). In 1985 Michael Criqui published the San Diego study\(^4\) showing a 25% mortality rate at 5 years in intermittent claudication (IC) and 50% from critical limb ischemia (CLI). Worryingly these figures are as true today as in 1985\(^5\) ie 34 years ago (Fig 1). Whilst morbidity and mortality from coronary disease continues to fall\(^6\), with mortality at 13% at 6 years, cardiovascular events in PAD have remained the same with the mortality rate persisting at 25%\(^7,8\) at 5yrs. This dichotomy reflects, in part, an inappropriate divergence from best clinical practice for patients with PAD compared to those with coronary artery disease.

Underdiagnosed.

There are a number of reasons why PAD is underdiagnosed\(^9\), with about 1/2 of patients having atypical pain\(^10\). Further this is an elderly population who themselves put ‘pain in the leg’s down to arthritis or ‘back troubles’. GPs can do the same, and understandably are reluctant to palpate peripheral pulses within a 10 min appointment slot, with the knowledge that 1/3\(^{rd}\) of palpations are wrong in inexperienced hands. So, PAD is an under-diagnosed disease, and the consequence of missing it is a missed opportunity to prevent future cardiovascular (CV) events.
Under-treated

Further, once diagnosed, PAD is grossly under-treated in terms of cardiovascular risk. The REACH Registry and other recent papers clearly link CV endpoints in PAD to poor risk management of these patients, and show improved outcome with positive management. Even within this past 12 months publications show disproportionate levels of fatal and non-fatal CV events. Again, there are a number of reasons for this, including in the UK the failure of the Quality Outcomes Framework (QoF) to include PAD in its outcome measures (only stroke and Cardiac disease recorded), and this neglect down-prioritised PAD diagnosis and treatment with, I believe, a hangover effect felt today.

Further secondary care for patients with PAD is delivered by Vascular Surgeons whose training is predominantly surgical, and it is only very recently that statin therapy and antiplatelet agents were introduced by Vascular Surgeons, and few surgeons treat to target (ie 40% decrease in non HDL as recommended by SIGN). Whilst some surgeons are excellent at managing risk, this is certainly not across the board and not to the same competency as in cardiology or via vascular physicians in mainland Europe where Angiology/Vascular Medicine is a sub-speciality of Internal Medicine in 16 EU Countries. Understandably a surgical training does not lend itself to vascular risk management with medical treatments. In summary compared to coronary disease, the sub-optimal management of vascular risk in these patients is well documented, resulting in an unacceptably high incidence of myocardial infarction, stroke, and cardiovascular (CV) death.

Proper diagnostics, medical, and interventional treatments as well as follow up, are a priority. Only a multidisciplinary approach with a strong SIGN Guideline targeted to those who actually manage these patients (Primary Care, Vascular Surgeons, and other Vascular clinicians) can address the problem.

The Problem is now compounded by recent trials of medical treatments to decrease amputation

Whilst one might assume that CV risk factor management could be managed with reference to SIGN Guideline I wonder how many Vascular Surgeons have read it? This could be an interesting study, but as not specifically targeted to them I doubt it will be many. However recent studies regarding the limb need to be brought to their attention as both the surgeon, and the patient, very much have the limb as a priority, for obvious reasons. Such evidence will, I believe significantly change surgical behaviour and enhance patient compliance when it can be shown that medical treatments benefit the limb.

So for example the 4S study showed that patients on a statin had less likelihood of developing IC, a few small but interesting studies, requiring critical evaluation, show increased walking distance with statins, better endovascular outcomes, again the studies requiring critical evaluation, and importantly fewer amputations in a number of large population based studies of intensive statin therapy (Fig 2)
Such a beneficial effect on the limb if emphasised in Guidelines (or not as per evidence) would greatly enhance surgical uptake and patient compliance.

Further other recent studies have shown medical treatment to not only decrease CV Events but also amputation. This includes the Fourier study\textsuperscript{24} with a PSCK9 inhibitor, and COMPASS\textsuperscript{25} with a vascular dose of rivaroxaban and aspirin.

**PAD Specific Treatment is neglected**

One of the most effective treatments for IC is structured exercise training. Do you know how many units offer this service? Very, very few, and yet the evidence is convincing\textsuperscript{26}, and it appears in all Guidelines\textsuperscript{27}. At best patients are offered cardiac rehab, for which there is no evidence, and at worst told to ‘go and exercise’ which has been shown to be ineffective. The need for careful podiatry and other management skills is recognised but not practised, again we are failing these patients.

**Summary: Why we need a specific PAD SIGN Guideline**

- PAD is underdiagnosed, if CV risk management is started before other organ damage ie heart attack and stroke, then outcome is much better.
- PAD is undertreated. This reflects the pathway of care management and a Guideline targeted to the clinicians who look after these patients is crucial
- This undertreatments leads to Cardiac and stroke events but also amputation. Newer treatments decrease limb events as well as CV events elsewhere
- Management of other aspects of PAD is sub-optimal eg structured exercise classes
- I am asking SIGN to redress this inequality of care

JJFB Sept 2019
References


10. Belch JJF, MacCuish A, Campbell I et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease

BMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a1840 (Published 16 October 2008)


